Skip to main content
SpringerLink
Log in

Traditional and Novel Possible Targets for Antidepressant Drugs

  • Chapter
  • First Online:
Herbal Medicine in Depression

Abstract

Antidepressant drugs have been available since the late 1950s. A large number of such drugs have been developed over the years. Unraveling their mechanism of action paved the way to the development of the earlier hypotheses of depression such as the monoamine theory and beta-receptor downregulation hypothesis. This led to yet more antidepressant drugs being produced, all of which worked via the noradrenergic and serotonergic systems. They increased monoamine neurotransmitter system activity usually by blocking the presynaptic reuptake mechanism, binding the monoamine oxidase intraneuronally or targeting specific receptors on the postsynaptic membrane.

Although generally effective, current antidepressants are successful in less than two thirds of depressed patients. More recent developments in the understanding of the pathophysiology of depression have stimulated a rethinking in the approach to drug development. Novel drugs need to take into account the current knowledge on brain dysfunction in relation to depression and target available and future biomarkers of this condition. Various avenues are being explored in keeping with the new approach of “precision medicine” with the view to develop drugs based on “molecular diagnoses.”

Depression is a multifactorial condition and not all abnormalities and biomarkers apply to all patients. The skill of future approaches to treatment would be to identify the specific abnormalities relevant to the individual patient and target these biomarkers with specific drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141:308–14.

    Article  CAS  PubMed  Google Scholar 

  • Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26:607–11.

    Article  CAS  PubMed  Google Scholar 

  • Amrein R, Allen SR, Vranesic D, Stahl M. Antidepressant drug therapy: associated risks. J Neural Transm. 1988;26(suppl):73–86.

    CAS  Google Scholar 

  • Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994;8:238–49.

    Article  CAS  PubMed  Google Scholar 

  • Axelrod J. Noradrenaline: fate and control of its biosynthesis. Les Prix Nobel 1970. Imprimerie Royale P. A. Norstedt & Soner, 1971; p. 189–208

    Google Scholar 

  • Baune BT, Caliskan S, Todder D. Effects fo adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with resistant depression. Hum Psychopharmacol Clin Exp. 2007;22:1–9.

    Google Scholar 

  • Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.

    Article  CAS  PubMed  Google Scholar 

  • Blier P, Bergeron R, de Montigny C. Selective activation of post-synaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology. 1997;16:333–8.

    Article  CAS  PubMed  Google Scholar 

  • Bloch RG, Doonief AS, Buchberg AS, Spellman S. The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann Intern Med. 1954;40:881–900.

    Article  CAS  PubMed  Google Scholar 

  • Boyer EW, Shannon M. The serotonin syndrome. N Eng J Med. 2005;352:1112–20.

    Article  CAS  Google Scholar 

  • Bremner JD, Narayan M, Anderson ER. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157:115–7.

    Article  CAS  PubMed  Google Scholar 

  • Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol. 1996;11 suppl 4:9–14.

    Article  PubMed  Google Scholar 

  • Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA. Urinary free-cortisol excretion in depression. Psychol Med. 1976;6:43–50.

    Article  CAS  PubMed  Google Scholar 

  • Celada P, Puia MV, Amargόs-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29:252–65.

    PubMed  PubMed Central  Google Scholar 

  • Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746–58.

    Article  CAS  PubMed  Google Scholar 

  • Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113:1237–64.

    Article  CAS  PubMed  Google Scholar 

  • Covvey JR, Crawford AN, Lowe DK. Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother. 2012;46:117–23.

    Article  CAS  PubMed  Google Scholar 

  • Crane GE. Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatr Res Rep Am Psychiatr Assoc. 1957;8:142–52.

    CAS  PubMed  Google Scholar 

  • Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm. 1988;26(suppl):31–56.

    Google Scholar 

  • DeBattista C, Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol Metab. 2006;17:117–21.

    Article  CAS  PubMed  Google Scholar 

  • DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs. 2009;23:369–77.

    Article  CAS  PubMed  Google Scholar 

  • Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990;47:411–8.

    Article  CAS  PubMed  Google Scholar 

  • Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, Charney DS. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull. 1993;29:389–96.

    CAS  PubMed  Google Scholar 

  • Dell’Orso B, Palazzo MC, Oldani L, Altamura AC. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther. 2011;17:723–32.

    Article  Google Scholar 

  • Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, Deckert J, Arolt V, McMahon FJ, Baune BT. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 2010;13:93–101.

    Article  CAS  PubMed  Google Scholar 

  • Dunlop BW, Nemeroff CB. The role of dopamine in the patho- physiology of depression. Arch Gen Psychiatry. 2007;64:327–37.

    Article  CAS  PubMed  Google Scholar 

  • Ellis JS, Zarate CA, Luckenbaugh DA, Furey ML. Antidepressant treatment history as a predictor of response to scopolamine:clinical implications. J Affect Disord. 2014;162:39–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Eyding D, Lelgemann M, Grouve U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010;341:4737.

    Article  Google Scholar 

  • Eyre HA, Air T, Proctor S, Rositano S, Baune BT. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2015;7:11–6.

    Article  Google Scholar 

  • Ferrier IN, Anderson IM, Barnes J, Gallagher P, Grunze HCR, Haddad PM, House AO, Hughes T, Lloyd AJ, Mamasoula C, McColl E, Pearce S, Siddiqi N, Sinha B, Speed C, Steen N, Wainwright J, Watson S, Winter FH, McAllister-Williams RH. Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of anti-depressants in depression (ADD study). Efficacy Mech Eval. 2015;2(4).

    Google Scholar 

  • Frodl T, Moller HJ, Meisenzahl E. Neuroimaging genetics: new perspectives in research on major depression? Acta Psychiatr Scand. 2008;118:363–72.

    Article  CAS  PubMed  Google Scholar 

  • Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63:1121–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev. 2008;1:CD005168.

    PubMed  Google Scholar 

  • Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57:99–104.

    CAS  PubMed  Google Scholar 

  • Goltser-Dubner T, Galili-Weisstub E, Segman RH. Genetics of unipolar major depressive disorder. Isr J Psychiatry Relat Sci. 2010;47:72–82.

    PubMed  Google Scholar 

  • Guiard BP, Mansari ME, Blier M. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets. 2009;10(1069-1084):1069.

    Article  CAS  PubMed  Google Scholar 

  • Gvozdic K, Brandl EJ, Taylor DL, Müller DJ. Genetics and personalized medicine in antidepressant treatment. Curr Pharm Des. 2012;18:5853–78.

    Article  CAS  PubMed  Google Scholar 

  • Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36(12):2452–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011;378:621–31.

    Article  CAS  PubMed  Google Scholar 

  • Hollon SD, Shelton RC, Wisniewski S, Warden D, Biggs MM, Friedman ES, Husain M, Kupfer DJ, Nierenberg AA, Petersen TJ, Shores-Wilson K, Rush AJ. Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatry Res. 2006;40:59–69.

    Article  Google Scholar 

  • Holsboer F, Ising M. Central CRH system in depression and anxiety- evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583:350–7.

    Article  CAS  PubMed  Google Scholar 

  • Insel TR, Bruce N. Brain disorders? Precisely Cuthbert. Science. 2015;348:499.

    Article  CAS  PubMed  Google Scholar 

  • Keating GM, Robinson DM. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs. 2007;67:1077–95.

    Article  CAS  PubMed  Google Scholar 

  • Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the ‘kindling’ hypothesis. Am J Psychiatry. 2000;157:1243–51.

    Article  CAS  PubMed  Google Scholar 

  • Krishnan KRR. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Arlington, VA: The American Psychiatric Publishing; 2004. p. 303–14.

    Google Scholar 

  • Kuhn R. The imipramine story. In: Ayd FJ, editor. Discoveries in biological psychiatry. Philadelphia, PA: Blackwell; 1970. p. 205–17.

    Google Scholar 

  • Loomer HP, Saunders JC, Kline NA. Clinical and pharmacological evaluation of iproniazid as a psychic energizer. In: Cleghorn RA, editor. Research in affects psychiatric research reports no 8 of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1957. p. 129–41.

    Google Scholar 

  • Maneeton M, Maneeton B, Srisurapanont M, Martin D. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry. 2012;12:160.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry. 2003;54:363–75.

    Article  PubMed  Google Scholar 

  • MHRA. Medicines and healthcare products regulatory agency-reboxetine: benefit-risk balance reviewed. Drug Safety Update. 2011;5(2):H1.

    Google Scholar 

  • Mitani H, Shirayama Y, Yamada T, Kawahara R. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol and serotonin turnover in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:531–4.

    Article  CAS  PubMed  Google Scholar 

  • Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry. 2002;51:775–87.

    Article  CAS  PubMed  Google Scholar 

  • Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11:680–4.

    Article  PubMed  Google Scholar 

  • Murphy BE. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol. 1991;39:239–44.

    Article  CAS  PubMed  Google Scholar 

  • Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:781–823.

    Article  CAS  PubMed  Google Scholar 

  • Narasimhan S, Loboff FW. Pharmacogenetics of antidepressant drugs. Pharmacogenomics. 2012;13:441–64.

    Article  CAS  PubMed  Google Scholar 

  • Nelson JC. Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry. 1998;59 suppl 5:65–8.

    CAS  PubMed  Google Scholar 

  • O’Dwyer AM, Lightman SL, Marks MN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 1995;33:123–8.

    Article  PubMed  Google Scholar 

  • Okuda A, Suzuki T, Kishi T, Yamanouchi Y, Umeda K, Haitoh H, Hashimoto S, Ozaki N, Iwata N. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci. 2010;64:268–73.

    Article  CAS  PubMed  Google Scholar 

  • Ortiz J, Mariscot C, Alvarez E, Artigas F. Effects of the antidepressant drug tianeptine on plasma and platelet serotonin of depressive patients and healthy controls. J Affect Disord. 1993;29:227–34.

    Article  CAS  PubMed  Google Scholar 

  • Pace WWT, Hu F, Miller A. Cytokine effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21:9–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Palazidou E. Quetiapine: a new option in bipolar depression. Future Prescriber. 2009;10(4):9–14.

    Article  Google Scholar 

  • Palazidou E. The neurobiology of depression. Br Med Bull. 2012;101(1):127–45.

    Article  CAS  PubMed  Google Scholar 

  • Palazidou E, Skene S, Arendt J. The acute and chronic affects of (þ)-and (2-)-oxaprotiline upon melatonin secretion in normal subjects. Psychol Med. 1992a;22:61–7.

    Article  CAS  PubMed  Google Scholar 

  • Palazidou E, Papadopoulos A, Radcliff H, Dawling S, Checkley SA. Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol Med. 1992b;22:309–15.

    Article  CAS  PubMed  Google Scholar 

  • Piccinni A, Del Debbio A, Medda P, Bianchi C, Roncaglia I, Veltri A, Zanello S, Massimetti E, Origlia N, Domenici L, Marazziti D, Dell'Osso L. Plasma brain-derived neurotrophic factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol. 2009;19:349–55.

    Article  CAS  PubMed  Google Scholar 

  • Pintor L, Gasto C, Navarro V, Torres X, Fañanas L. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord. 2003;73:237–44.

    Article  PubMed  Google Scholar 

  • Porcelli S, Fabbri C, Drago A, Gibiino S, De Ronchi D, Serretti A. Genetics and antidepressants; where we are. Clin Neuropsychiatry. 2011;2:99–150.

    Google Scholar 

  • Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry. 2001;62:358–61.

    Article  CAS  PubMed  Google Scholar 

  • Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry. 2012;2012:1–11.

    Google Scholar 

  • Rothman RB. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci. 1990;46:17–21.

    Article  Google Scholar 

  • Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.

    Article  PubMed  Google Scholar 

  • Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology of mood disorders. Neuropsychopharmacology. 2012;62:63–77.

    CAS  Google Scholar 

  • Sanchez C, Asin K, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.

    Article  CAS  PubMed  Google Scholar 

  • Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509–22.

    Article  CAS  PubMed  Google Scholar 

  • Seth R, Jennings AL, Bindman J, Phillips J, Bergman K. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992;161:562–5.

    Article  CAS  PubMed  Google Scholar 

  • Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70–5.

    Article  CAS  PubMed  Google Scholar 

  • Skolnick P, Popic P, Janowsky A, Beer B, Lippa AS. “Broad spectrum” antidepressants: is more better for the treatment of depression? Life Sci. 2003;73:3175–9.

    Article  CAS  PubMed  Google Scholar 

  • Soczynska JK, Mansur RB, Brietzke E, et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res. 2012;235:302–17.

    Article  CAS  PubMed  Google Scholar 

  • Thakore JH, Dinan T. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry. 1995;37:364–8.

    Article  CAS  PubMed  Google Scholar 

  • Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–41.

    Article  CAS  PubMed  Google Scholar 

  • Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol. 2013;28:113.

    Article  PubMed  Google Scholar 

  • Vaishnavi SN, Nemeroff C, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55(3):320–2.

    Article  CAS  PubMed  Google Scholar 

  • Vetulani J, Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature. 1975;257:495–6.

    Article  CAS  PubMed  Google Scholar 

  • Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry. 1999;45:1070–4.

    Article  CAS  PubMed  Google Scholar 

  • Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.

    Article  CAS  PubMed  Google Scholar 

  • Zarate Jr CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Barts & London School of Medicine, Queen Mary University, London, UK

    Eleni Palazidou MD, PhD, MRCP, FRCPSYCH

Authors
  1. Eleni Palazidou MD, PhD, MRCP, FRCPSYCH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eleni Palazidou MD, PhD, MRCP, FRCPSYCH .

Editor information

Editors and Affiliations

  1. REQUIMTE/LAQV Lab Pharm Dep Chem Fac Pha, University of Porto, City, Grande Porto, Portugal

    Clara Grosso

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Palazidou, E. (2016). Traditional and Novel Possible Targets for Antidepressant Drugs. In: Grosso, C. (eds) Herbal Medicine in Depression. Springer, Cham. https://doi.org/10.1007/978-3-319-14021-6_2

Download citation

Publish with us

Policies and ethics

Search

Navigation